PharmaCyte Biotech appoints Dr. Matthias Löhr to Board to fill vacancy from Yuen's death
PharmaCyte Biotech, Inc.
Dr. Löhr appointed to Board on March 31, 2022; vacancy created by death of Thomas C.K. Yuen.
Compensation: $12,500 cash per quarter, annual grant of 334 restricted shares and a 5-year option for 334 shares (fully vested).
Dr. Löhr is Professor of Gastroenterology & Hepatology at Karolinska Institute; led prior Phase 1/2 and Phase 2 trials of the company's pancreatic cancer treatment.
He will serve on the Compensation and Nominating Committees; independence under Nasdaq rules confirmed.
No family relationships or related party transactions with the company disclosed.
On March 31, 2022, the Board of Directors ("Board") of PharmaCyte Biotech, Inc., a Nevada corporation ("Company"), appointed Matthias Löhr, MD ("Dr. Löhr") to the Board to fill a vacancy
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Thomas C.K. Yuen departed as Director at PharmaCyte Biotech, Inc..
Action
deceased
Role
Director
Exact text from the filing
vacancy created by the recent death of Thomas C.K. Yuen
Matthias Löhr was appointed as Director at PharmaCyte Biotech, Inc..
Action
appointed
Role
Director
Exact text from the filing
On March 31, 2022, the Board of Directors ("Board") of PharmaCyte Biotech, Inc., a Nevada corporation ("Company"), appointed Matthias Löhr, MD ("Dr. Löhr") to the Board to fill a vacancy
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.